Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup

pharmafile | April 7, 2016 | News story | Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire 

Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in the backdrop of new US Treasury Department rules announced Monday.

Shire said it expects to complete the transaction by mid-2016. The Shire-Baxalta merger is targeted at creating a biotechnology firm focused on rare diseases, the company said in a statement. 

In January, Baxalta agreed a takeover by Shire following months of wooing. 

US regulators have implemented new regulations in a bid to control tax inversions that has led to the termination of $160 billion Pfizer (NYSE: PFE) deal with Dublin-based Allergan (NYSE: AGN).

However, this isn’t the first time government action in the US has derailed a pharma transaction. In 2014, a similar regulatory implementation led to Abbvie (NYSE: ABBV) calling off its $52 billion takeover of Shire.  Previously, Shire and AbbVie agreed to terminate a merger accord following previous changes introduced in September to US tax rules.

Anjali Shukla

Related Content

AbbVie to acquire ImmunoGen for approximately $10.1bn

AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy …

Aldeyra Therapeutics and AbbVie enter agreement for development and commercialisation of reproxalap

Aldeyra Therapeutics and AbbVie have announced that they have entered into an exclusive option agreement …

CDC Advisory Committee recommends Pfizer’s RSV vaccine

Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee …

Latest content